Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
122
datasets available to search
ShareScore release 0.9.0
Dataset results
122 results for “Alzheimer's disease','Cognitive impairment”
Atrophy Pattern Maps of Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, and Frontotemporal Dementia
<p>The files contain voxel-wise t-statistics maps contrasting deformation based morphometry (DBM) measurements of Alzheimer's disease (AD), Parkinson's disease (PD), mild cognitive impairment (MCI), and fronto-temporal dementia (FTD) patients against matched normal controls.</p> <p>AD and MCI maps are based on ADNI data, available at:</p> <p>PD map is based on PPMI data, available at:</p> <p>FTD map is based on NIFD data, available at:</p> <p>For more information regarding the participants and method details, see:</p> <p>Dadar, Mahsa, et al. "White matter hyperintensities are associated with grey matter atrophy and cognitive decline in Alzheimer's disease and frontotemporal dementia." <em>Neurobiology of aging</em> 111 (2022): 54-63.</p>
Resting-State High-Density EEG using EGI GES 300 with 256 Channels of Healthy Elders, People with Subjective and Mild Cognitive Impairment and Alzheimer's Disease
<p>This repository contains Matlab files including 4 samples of resting-state EEG recording for Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD), and Healthy Controls (HC) using the HD-EEG EGI GES 300.</p> <p><strong>[AD: i108, MCI: i100, SCD: i090, HC: s055]</strong></p> <p> </p> <p><strong>Participants & Settings</strong></p> <p>In total 230 participants have been recruited from the memory and dementia clinic of the Greek Association of Alzheimer’s Disease and Related Disorders (GAADRD) and the 1st Department of Neurology, U.H. AHEPA, Aristotle University of Thessaloniki, Greece.</p> <p>The full dataset includes:</p> <p><strong>Healthy Controls Elders (60+ years old)</strong>: 33 participants</p> <p><strong>Subjective Cognitive Decline:</strong> 34 participants</p> <p><strong>Mild Cognitive Impairment</strong>: 79 participants</p> <p><strong>Alzheimer's Disease</strong>: 48 participants</p> <p><strong>Healthy Young (25-40 years old):</strong> 36 participants</p> <p>The study was carried out in accordance with the Declaration of Helsinki and received approval by the Scientific and Ethics Committee of GAADRD (No56_27/11/2016), and written informed consent was obtained from all participants prior to their participation in the study. The diagnosis of AD was conducted by a neuropsychiatrist according to their medical history, neuropsychological performance, structural magnetic resonance imaging (MRI), and clinical and neurological examinations.</p> <p>Participants with AD fulfilled the National Institute of Neurological and Communication Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD, as well as the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria for dementia of Alzheimer’s type (American Psychological Association, 1994). On the other hand, the MCI participants fulfilled the Petersen criteria, while the SCD group met International Working Group-2 guidelines and the recent National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease (NI-AA), as well as the SCD-I Working Group instructions. </p> <p><strong>Resting-State EEG Recording</strong></p> <p>Fifteen-minute resting EEG activity was recorded for all the participants. For the whole duration of the resting state EEG recording, participants were advised to keep themselves relaxed as much as possible, close their eyes and open them after the researcher’s demand, sit still, minimize blinking or mouth movements and let their mind wander. The experimental procedure was monitored by a research assistant aiming to identify cases of horizontal eye movements, continued blinking, or excessive movement by visually inspecting the EEG traces during the experiment. More specifically, an EEG was registered for both resting conditions (eyes open, EO and eyes closed, EC) for at least 2–3 min for each period.</p> <p><strong>EEG Data Acquisition</strong></p> <p>The EEG data were collected by using the EGI 300 Geodesic EEG system (GES 300, CERTH-ITI, Thessaloniki, Greece) with a 256-channel HydroCel Geodesic Sensor Net (HCGSN) and a sampling rate of 250 Hz (EGI Eugene, OR). Moreover, the researcher placed the electrodes in accordance with the 256 HCGSN adult 1.0 montage system, while the signals were recorded relative to a vertex reference electrode (Cz), with AFz as the ground electrode with the electrodes’ impedance below 50 kΩ throughout the experimental procedure, as recommended for the high-input impedance amplifier. In detail, the HD-EEG data were analyzed offline in order to detect any artifact, as well as to conduct pre-processing (filtering, segmentation, bad channel replacement) using Net Station 4.3 software (EGI). HD-EEG data were initially filtered with a 5th-order bandpass Butterworth IIR filter of 0.3–30 Hz. Once the segmentation was completed, the detection of artifacts was performed by using the Net Station artifact detection tool for the automatic detection of excessive eye blinking and movement. Afterward, the signals were baseline corrected using 200 msec before the start of the experiment period and average re-referenced to transform them into reference-independent values.</p> <p> </p> <p><strong>Full Dataset Access</strong></p> <p>More information about the sample dataset and access to the full dataset can be available after request via e-mail:</p> <p><strong>Ioulietta Lazarou</strong> BSc, MSc, PhD candidate</p> <p>Neuropsychologist - Clinical Research Associate </p> <p>Centre for Research and Technology Hellas (CERTH), Information Technologies Institute (ITI)</p> <p>6th km Charilaou-Thermi Road, P.O. Box 60361, 57001 Thermi-Thessaloniki, Greece</p> <p>E-mail: <a href="mailto:iouliettalaz@iti.gr">iouliettalaz@iti.gr</a></p>
OpenData for the Independent morphological variables correlate to aging, Mild Cognitive Impairment, and Alzheimer's Disease manuscript
<p>Results from processed structural MRI images from the <a href="https://www.sciencedirect.com/science/article/pii/S1053811920306868">AHEAD</a> and <a href="https://www.nature.com/articles/s41597-021-00870-6">AOMIC</a> dataset included in the Supplementary Information at the Independent morphological variables correlate to aging, Mild Cognitive Impairment, and Alzheimer's Disease manuscript from de Moraes et al. submitted to PNAS.</p> <p>For this data, we processed the datasets with <a href="https://surfer.nmr.mgh.harvard.edu/">FreeSurfer</a> v6.0.0 standard processing pipeline (<em>recon-all</em>) and the estimation of the <a href="https://surfer.nmr.mgh.harvard.edu/fswiki/LGI">local Gyrification Index</a> from <a href="http://ltswww.epfl.ch/~schaer/Schaer_TMI.pdf">Schaer, M. et al. 2008</a>. We further extracted the morphological measurements from the generated surfaces using the Cortical Folding Analysis Tools from <a href="https://zenodo.org/record/3608675">Wang et al. 2019</a>. Here, we included the raw morphological datasets joined with the demographics and subjects' information.</p>
Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease
ClinicalTrials.gov study NCT02380573. IPD Sharing: Not stated. Countries: 1. Publications: 15.
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
ClinicalTrials.gov study NCT02503501. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease
ClinicalTrials.gov study NCT01028053. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
ClinicalTrials.gov study NCT02423200. IPD Sharing: Not stated. Countries: 1. Publications: 1.
BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
ClinicalTrials.gov study NCT02788513. IPD Sharing: Not stated. Countries: 14. Publications: 1.
A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease
ClinicalTrials.gov study NCT03019536. IPD Sharing: Not stated. Countries: 3. Publications: 1.
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
ClinicalTrials.gov study NCT01931566. IPD Sharing: YES. Countries: 5. Publications: 2.
BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
ClinicalTrials.gov study NCT02337907. IPD Sharing: Not stated. Countries: 11. Publications: 1.
Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease
ClinicalTrials.gov study NCT03319810. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
ClinicalTrials.gov study NCT04971733. IPD Sharing: YES. Countries: 2. Publications: 0.
PubChem lists to Study the Exposome of Mild Cognitive Impairment and Alzheimer's Disease on Cerebrospinal Fluid
<p>Collection of 4 lists of chemicals associated to Alzheimer's disease (AD) and related disorders. </p> <p>The following table describes the mentioned lists. </p> <table> <tbody> <tr> <td>Name</td> <td>Description</td> </tr> <tr> <td>AD-database</td> <td>Database of 41,917 chemicals related to AD and other neurodegenerative disorders. CIDs co-ocurring with the 27 selected MeSH terms (*see below) were merged and mapped to the parent CIDS.</td> </tr> <tr> <td>TOP1</td> <td>List of 1,268 chemicals having D000544 (AD MeSH code) as the first neighbor .</td> </tr> <tr> <td>SC20</td> <td>List of 247 chemicals created after truncating by 1/20 of the maximum co-ocurrence score of the chemical neighbors for D000544. </td> </tr> <tr> <td>AD-CTD</td> <td>List of 86 chemicals specifically related to AD in the Comparative Toxicogenomic Database (CTD)</td> </tr> </tbody> </table> <p> *Selected MeSH terms for the AD-database: D000647,D000647,D000647,D000647,D000647,D000647,D000647,D000647,D000647,D000647,D000647,D000647,D000647,D000647,D000647,D000647,D000647,D000647,D000647,D000647,D000647,D000647,D000647,D000647,D000647,D000647 and D000647.</p> <p>HMDB-CSF can be downloaded <a href="https://csfmetabolome.ca/downloads"><strong>here</strong></a>.</p> <p>PubChemLite for Exposomics (version 1.12.0) can be found <a href="https://doi.org/10.5281/zenodo.6936117"><strong>here</strong></a>.</p>
Evaluation of Safety of Contraloid Acetate in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
ClinicalTrials.gov study NCT04711486. IPD Sharing: NO. Countries: 1. Publications: 1.
Music Therapy Experiences in Patients With Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)
ClinicalTrials.gov study NCT04666077. IPD Sharing: NO. Countries: 1. Publications: 1.
Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment
ClinicalTrials.gov study NCT02573740. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Amyloid and Glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients With Significant White Matter Disease
ClinicalTrials.gov study NCT02330510. IPD Sharing: Not stated. Countries: 1. Publications: 6.
Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease
ClinicalTrials.gov study NCT04795466. IPD Sharing: YES. Countries: 4. Publications: 0.
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
ClinicalTrials.gov study NCT05040217. IPD Sharing: NO. Countries: 1. Publications: 5.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.